Skip to main content

For your cataract surgery patients

ILEVRO bottle next to packaging

Get Your
Patients Started

Widely available, well covered, and backed by Harrow, ILEVRO® is available on tiered and preferred coverage plans.*

Largest Branded Ophthalmic NSAID Clinical Trial Program1-3†

Review results from 2 trials of 2,928 adult patients undergoing cataract surgery.1,4

Data provided through MMIT and are current as of 2/2024. The information provided in this website is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation or warranty of any kind by any plan or insurer referenced herein.

Since 2005.1 
 

References: 1. ILEVRO (nepafenac ophthalmic suspension) 0.3% [package insert]. Harrow IP, LLC; 2023. 2. BromSite (bromfenac ophthalmic solution) 0.075% [package insert]. Cranbury, NJ: Sun Pharma Global FZE; 2016. 3. Prolensa (bromfenac ophthalmic solution) 0.07% [package insert]. Bridgewater, NJ: Bausch & Lomb; 2016. 4. Data on file. Harrow IP, LLC; 2023.

References: 1. ILEVRO (nepafenac ophthalmic suspension) 0.3% [package insert]. Harrow IP, LLC; 2023. 2. BromSite (bromfenac ophthalmic solution) 0.075% [package insert]. Cranbury, NJ: Sun Pharma Global FZE; 2016. 3. Prolensa (bromfenac ophthalmic solution) 0.07% [package insert]. Bridgewater, NJ: Bausch & Lomb; 2016. 4. Data on file. Harrow IP, LLC; 2023.